Telomerase Modulating of Breast Cancer Through Nano-Based Drug Delivery System

Breast cancer (BC) is the second cancer-dyeing reason among women worldwide. Surgical, radiation, and medicine-based approaches are the current methods for BC treatment; however, they did not overcome metastasis BC robustly. Finding treatments to improve the survival rate appears to be an essential attitude. Telomer is a fundamental part of the linear eukaryote chromosome. Despite the low-telomerase activity in somatic cells, it has been reported that more than 90% of human cancer cells represented high telomerase activity that leads to a low prognosis of BC. As such, telomerase targeting agents have attracted much attention to developing new specific anti-cancer for BC therapy. Science the excellent outputs of Imetelstat as an anti-cancer drug; researchers have focused on developing new anti-telomerase agents, such as hTERT-based immunotherapeutic agents. Telomerase modulation in BC is a new treatment approach and is progresses by developing small molecules, immunotherapeutic, targeting catalytic subunit (hTERT-based agents), or RNA template targeting. Furthermore, new therapeutic agents can be manipulated to obtain a targeting system. Nanotechnology has paved the way to engineer targeting systems to overcome traditional challenges. There are various ongoing studies targeting hTERT using nanoparticles (NPs) to restrict cancer progress. Different types of nanoparticles, including polymeric, liposomes, metal, nanofibrous scaffolds, and QDs, have been investigated. According to the previous literature, NPs with appropriate designs lead to enhance anti-telomerase activity efficacy of medicines. Here, we have reviewed the importance of telomerase activity during BC tumorigenicity and also the impact of telomerase inhibitors and NP-based formulation for BC therapy.